Exhibits histone deacetylase binding activity and transcription factor binding activity. Involved in cellular response to fibroblast growth factor stimulus; osteoblast differentiation; and positive regulation of ossification. Localizes to the nucleus. Human ortholog(s) of this gene implicated in cleidocranial dysplasia. Orthologous to human RUNX2 (RUNX family transcription factor 2); PARTICIPATES IN fibroblast growth factor signaling pathway; transforming growth factor-beta Smad dependent signaling pathway; INTERACTS WITH (20S)-ginsenoside Rg3; 2,3,7,8-tetrachlorodibenzodioxine; 3-chloropropane-1,2-diol.
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]] more ...
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RUNX2 mRNA]
AHR protein affects the reaction [Tetrachlorodibenzodioxin results in decreased expression of RUNX2 mRNA], Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to RUNX2 gene]
4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein]
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]
4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein]
[EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA, [EPO protein co-treated with Glucose] results in increased expression of RUNX2 protein
anacardic acid inhibits the reaction [Tretinoin results in increased expression of RUNX2 mRNA], ginkgolic acid inhibits the reaction [Tretinoin results in increased expression of RUNX2 mRNA]
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA], DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]
4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein]
dorsomorphin inhibits the reaction [Bezafibrate results in increased expression of RUNX2 mRNA], GSK0660 inhibits the reaction [Bezafibrate results in increased expression of RUNX2 mRNA]
CYP27B1 protein promotes the reaction [Calcifediol results in increased expression of RUNX2 mRNA], Ketoconazole inhibits the reaction [Calcifediol results in increased expression of RUNX2 mRNA]
[Celecoxib results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 mRNA, [Celecoxib results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 protein
Cisplatin promotes the reaction [jinfukang results in decreased expression of RUNX2 mRNA], jinfukang promotes the reaction [Cisplatin results in decreased expression of RUNX2 mRNA]
Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA], Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]
4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein]
[EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA, [EPO protein co-treated with Glucose] results in increased expression of RUNX2 protein
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA, EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]
[Genistein co-treated with Ethanol] results in increased expression of RUNX2 mRNA, [Genistein co-treated with Ethanol] results in increased expression of RUNX2 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]
[Genistein co-treated with Ethanol] results in increased expression of RUNX2 mRNA, [Genistein co-treated with Ethanol] results in increased expression of RUNX2 protein
[EPO protein co-treated with Glucose] results in increased expression of RUNX2 mRNA, [EPO protein co-treated with Glucose] results in increased expression of RUNX2 protein
DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]], naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]
Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA], Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]]
Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA], Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]
PTH protein promotes the reaction [Vitamin K 2 results in increased expression of RUNX2 protein], Vitamin K 2 affects the reaction [PTH protein results in increased expression of RUNX2 protein]
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA
DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]], naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 mRNA, [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 protein
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA
rottlerin inhibits the reaction [FGF2 protein results in increased activity of RUNX2 protein], rottlerin inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA]
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]
DKK1 protein inhibits the reaction [Sodium Fluoride results in increased expression of RUNX2 mRNA], DKK1 protein inhibits the reaction [Sodium Fluoride results in increased expression of RUNX2 protein]
[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of RUNX2 mRNA, [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of RUNX2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA
[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA, Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA]
Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA], Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Gene-Chemical Interaction Annotations
